 |
 |
 |
 |
 |
 |
 |
 |
Potentia is an early stage biotechnology company focused on developing innovative therapeutics, primarily in the area of age-related macular degeneration and other inflammatory ocular diseases. Potentia assembles its pipeline of anti-inflammatory products through a combination of in-licensing of preclinical compounds and in-house research and development.
The safety of Potentia's POT-4, a small cyclic synthetic peptide, was confirmed by the ASaP Phase I clinical trial conducted in wet AMD patients at multiple sites across the United States.
The ASaP trial was recently completed and POT-4 was well tolerated in all patients at all doses.
more info on POT-4 »
- October 2009 Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
more » - July 2009 It is with great sadness that we say farewell to Dr. Armen Tashjian, who passed away on July 3, 2009. Dr. Tashjian was a brilliant scientist, a wonderful human being and a great friend and was instrumental in the successful development of POT-4 and the growth of our company. Our thoughts and prayers go out to his wonderful family. We will miss him.
- May 2009 Potentia Pharmaceuticals' POT-4 Drug Candidate for Age-Related Macular Degeneration Successfully Completes Phase I Clinical Trial - Prepares for Phase II
more »
